Clearside starts Phase II trial of CLS-TA to treat macular edema associated with RVO
US-based biopharmaceutical firm Clearside Biomedical has started patient enrolment in a Phase II trial of its proprietary formulation of triamcinolone acetonide, CLS-TA, to treat macular edema associated with retinal vein occlusion (RVO). (Source: Drug Development Technology)
Source: Drug Development Technology - March 3, 2015 Category: Pharmaceuticals Source Type: news

Is A Specific Corticosteroid Better for Treatment of Asthma Than Another?
Discussion Asthma is a chronic obstructive lung disease that affects many children and adults. There is a wide range of symptoms that people experience from occurring relatively rarely (ie intermittent asthma) to patients having daily symptoms of such intensity that they are life-threatening (ie chronic severe asthma). The goals of asthma management include patient education and medication management so patients have no or minimal symptoms, prevent exacerbations, have no activity restrictions, have normal pulmonary function tests, have no or minimal medication side effects and meet patient and family expectations. Well con...
Source: PediatricEducation.org - January 5, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Flexion Therapeutics starts Phase IIb trial of pain drug to treat osteoarthritis
US-based Flexion Therapeutics has dosed its first patient in a confirmatory Phase IIb clinical trial of its new, non-opioid, sustained-release, intra-articular (IA) formulation of triamcinolone acetonide (TCA) 'FX006' as a treatment for relieving paiā€¦ (Source: Drug Development Technology)
Source: Drug Development Technology - April 30, 2014 Category: Pharmaceuticals Source Type: news

Nasacort Allergy Spray Going OTC
(MedPage Today) -- The allergy nasal spray triamcinolone acetonide (Nasacort AQ) has been cleared for over-the-counter sale, drugmaker Sanofi announced. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - October 12, 2013 Category: Allergy & Immunology Source Type: news

FDA Panel Favors Nasacort OTC Switch
(MedPage Today) -- SILVER SPRING, Md. -- An FDA advisory committee voted Wednesday to make allergy nasal spray triamcinolone acetonide (Nasacort AQ) available without a prescription -- but some expressed concern about its use in children. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - August 2, 2013 Category: Allergy & Immunology Source Type: news

Nasacort Allergy Spray Can Go OTC, FDA Panel Says
A federal advisory panel has voted to allow Nasacort AQ (triamcinolone acetonide) nasal spray to be switched from prescription to over-the-counter. (Source: WebMD Health)
Source: WebMD Health - August 1, 2013 Category: Consumer Health News Source Type: news

Triamcinolone Nasal Spray Can Go OTC, FDA Panel SaysTriamcinolone Nasal Spray Can Go OTC, FDA Panel Says
The FDA Nonprescription Drugs Advisory committee voted to allow the steroid nasal spray to be sold without prescription, but only if the label clearly informs users about inappropriate use and potential risks to children. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 1, 2013 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

OTC Nasacort to Get FDA Panel Scrutiny
WASHINGTON (MedPage Today) -- FDA staff reviewers had few questions about making allergy nasal spray triamcinolone acetonide (Nasacort AQ) available for over-the-counter sales; later this week an advisory committee will look at the issue. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - July 30, 2013 Category: Allergy & Immunology Source Type: news

Nasacort AQ (Triamcinolone Acetonide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 22, 2013 Category: Drugs & Pharmacology Source Type: news

Platelet-Rich Plasma Boosts Hair Growth in Alopecia AreataPlatelet-Rich Plasma Boosts Hair Growth in Alopecia Areata
Alopecia areata, inflammation-induced hair loss, improved more with platelet-rich plasma (PRP) than with triamcinolone acetonide in a recent trial. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 30, 2013 Category: Consumer Health News Tags: Dermatology News Source Type: news